Skip to Content
Merck

Skip To

SML2227

Emricasan

≥98% (HPLC), powder, pan-caspase inhibitor

Synonym(s):

IDN-6556, N-[2-(1,1-dimethylethyl)phenyl]-2-oxoglycyl-N-[(1S)-1-(carboxymethyl)-2-oxo-3-(2,3,5,6-tetrafluorophenoxy)propyl]-L-Alaninamide, PF-03491390

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C26H27F4N3O7
CAS Number:
Molecular Weight:
569.50
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

Emricasan, ≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

SMILES string

CC(C)(C)C1=C(NC(C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O)=O)=O)=O)C=CC=C1

InChI

1S/C26H27F4N3O7/c1-12(31-24(38)25(39)32-16-8-6-5-7-13(16)26(2,3)4)23(37)33-17(10-19(35)36)18(34)11-40-22-20(29)14(27)9-15(28)21(22)30/h5-9,12,17H,10-11H2,1-4H3,(H,31,38)(H,32,39)(H,33,37)(H,35,36)/t12-,17-/m0/s1

InChI key

SCVHJVCATBPIHN-SJCJKPOMSA-N

Biochem/physiol Actions

Antiapoptotic caspase inhibitor; Pan-Caspase Inhibitor
Emricasan is an antiapoptotic pan-caspase inhibitor. It has been in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with advanced fibrosis (scarring) and cirrhosis. Emricasan has also been shown to protect infected astrocytes from ZIKV-induced cell death.
Emricasan, formerly known as IDN-6556, in combination with birinapan is used to treat acute myeloid leukemia (AML). This small molecule irreversible inhibitor is under clinical investigation to reduce hepatic injury and liver fibrosis.

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
SML2754SML0607A2731
form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

2-8°C

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: >5 mg/mL

shipped in

wet ice

shipped in

-

shipped in

wet ice

shipped in

-

color

white to beige

color

white to beige

color

white to beige

color

white to beige


Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Carcinogenicity assessment of the pan-caspase inhibitor, emricasan, in Tg.rasH2 mice
Elbekai RH, et al.
Regulatory Toxicology and Pharmacology, 72, 169-178 (2015)
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia
Brumatti G, et al.
Science Translational Medicine, 8, 339ra69-339ra69 (2016)
Haiyan Zhang et al.
Frontiers in cardiovascular medicine, 8, 685434-685434 (2021-08-03)
Dexrazoxane (DXZ) reduces cytotoxicity caused by Doxorubicin (DOX). However, the mechanism of DXZ in ferroptosis and cardiomyopathy remains unclear. This research, therefore, explores the role and mechanism of DXZ in DOX-induced ferroptosis and cardiomyopathy in rats. Kaplan-Meier survival analysis was



Global Trade Item Number

SKUGTIN
SML2227-25MG04061835503582
SML2227-5MG04061835503599

Questions

Reviews

No rating value

Active Filters